Work

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

Year: 2019

Type: article

Abstract: In recent months, cases of IBD have been reported in the context of treatment with secukinumab, a monoclonal antibody that blocks IL-17A and which is used in the treatment of certain rheumatic disorders. We present a case of a patient with psoriatic arthritis, with a first-degree relative who had suffered ulcerative colitis, who presented with onset ulcerative colitis in the weeks following treatment initiation with this drug.

Source: Revista Española de Enfermedades Digestivas

DOI: 10.17235/reed.2019.5841/2018

Authors: Rafael Rodríguez Moncada, Juan María Vázquez Morón, Héctor Pallarés Manrique

Institution: Hospital Juan Ramón Jiménez

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2963963931

FWCI: 2.367

Cites: 5

Cited by: 20

Related to: 10